Table 4 Real-life application—metastatic tumours

From: Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT)

Category Subcategory mCRC (n = 237) NET (n = 58) Breast (n = 47) Pancreatic (n = 32) Melanoma (n = 32) Other liver metastases (n = 79) All (n = 485)
Time since metastatic diagnosis (days) Median 438 1242 1089 514 84 437 579
Q1, Q3 230, 785 441, 2196 386, 2297 258, 850 56, 315 281, 877 253, 1089
Missing 39 (16.5%) 12 (20.7%) 7 (14.9%) 7 (21.9%) 1 (3.1%) 11 (13.9%) 77 (15.9%)
Intention of treatmentc Ablation 18 (7.6%) 5 (8.6%) 3 (6.4%) 2 (6.3%) 6 (7.6%) 34 (7.0%)
Bridge to liver surgery 2 (0.8%) 2 (0.4%)
Bridge to liver transplant 0 (0.0%)
Downsizing/down-staging 41 (17.3%) 4 (6.9%) 4 (8.5%) 9 (28.1%) 3 (9.4%) 13 (16.5%) 74 (15.3%)
Palliative 176 (74.3%) 49 (84.5%) 40 (85.1%) 21 (65.6%) 29 (90.6%) 60 (75.9%) 375 (77.3%)
Prior TARE hepatic procedures Yes 86 (36.3%) 27 (46.6%) 11 (23.4%) 14 (43.8%) 1 (3.1%) 24 (30.4%) 163 (33.6%)
No 150 (63.3%) 31 (53.4%) 36 (76.6%) 18 (56.3%) 31 (96.9%) 55 (69.6%) 322 (66.2%)
Missing 1 (0.4%) 1 (0.2%)
Surgical (any)a 67 (28.3%) 15 (25.9%) 5 (10.6%) 5 (15.6%) 16 (20.3%) 108 (22.2%)
Ablation (any) 27 (11.4%) 4 (6.9%) 2 (4.3%) 6 (18.8%) 1 (3.1%) 6 (7.6%) 46 (9.5%)
TACE (any) 3 (1.3%) 2 (3.4%) 2 (4.3%) 1 (3.1%) 8 (1.6%)
Vascular (any) 3 (1.3%) 3 (5.2%) 1 (2.1%) 7 (1.4%)
Abdominal radiotherapy (any) 6 (2.5%) 3 (5.2%) 4 (8.5%) 3 (9.4%) 5 (6.3%) 21 (4.3%)
Prior systemic therapy Yes 226 (95.4%) 47 (81.0%) 47 (100%) 27 (84.4%) 13 (40.6%) 67 (84.8%) 427 (88.0%)
No 11 (4.6%) 11 (19.0%) 5 (15.6%) 19 (59.4%) 12 (15.2%) 64 (12.0%)
Concomitant chemotherapyb Yes 31 (13.1%) 7 (12.1%) 6 (12.8%) 4 (12.5%) 4 (12.5%) 12 (15.2%) 64 (13.2%)
No 206 (86.9%) 51 (87.9%) 41 (87.2%) 28 (87.5%) 28 (87.5%) 67 (84.8%) 421 (86.8%)
Post-TARE systemic therapy Yes 87 (36.7%) 16 (27.6%) 20 (42.5%) 7 (21.9%) 12 (37.5%) 28 (35.4%) 170 (35.1%)
No 106 (44.7%) 34 (58.6%) 21 (44.7%) 19 (59.4%) 17 (53.1%) 42 (53.2%) 239 (49.3%)
Missingd 44 (18.6%) 8 (13.8%) 6 (12.8%) 6 (18.7) 3 (9.4%) 9 (11.4%) 76 (15.7%)
Post-TARE hepatic procedures Yes 35 (14.8%) 10 (17.2%) 3 (6.4%) 5 (15.6%) 5 (15.6%) 9 (11.4%) 67 (13.8%)
No 159 (67.1%) 40 (69.0%) 38 (80.9%) 21 (65.6%) 24 (75.0%) 61 (77.2%) 333 (70.5%)
Missingd 43 (18.1%) 8 (13.8%) 6 (12.8%) 6 (18.7) 3 (9.4%) 9 (11.4%) 76 (15.7%)
Surgical (any)a 10 (4.2%) 1 (1.7%) 1 (3.1%) 12 (2.5%)
Ablation (any) 11 (4.6%) 1 (2.1%) 1 (3.1%) 1 (1.3%) 14 (2.9%)
TACE (any) 6 (2.5%) 1 (3.1%) 1 (1.3%) 8 (4.2%)
Vascular (any) 2 (0.8%) 1 (1.7%) 3 (9.4%)   15 (1.6%)
Abdominal radiotherapy (any) 10 (4.2%) 7 (12.1%) 2 (4.3%) 4 (12.5%) 4 (5.1%) 27 (5.6%)
  1. aPatients can have multiple prior and post-TARE hepatic procedures
  2. bConcomitant if systemic therapy start date is within 4 weeks of first TARE treatment start date and up to 8 weeks after first TARE end date (where end date is within 42 days of first TARE in case of two sessions)
  3. cIntention of TARE is for first treatment
  4. dMissing data include data from patients that were lost to follow up or deceased before the first follow-up could be included (n = 76)